Very limited evidence comes from clinical studies; our group evaluated both cerebrospinal fluid (CSF) and plasma concentration of Gas6 of MS patients by an enzyme-linked immunosorbent assay (ELISA) validated for human use and tested in other diseases and in CSF [107,108,109]. This evidence concerns the gene GAS6 and myeloid sarcoma.